Method for the qualitative and/or quantitative determination of disease indicators, characterized in that a sample is analysed for at least two aggregate types of endogenous misfolded proteins, wherein the at least two aggregate types of endogenous misfolded proteins are selected from the group consisting of tau aggregates and α-synuclein aggregates and mixed aggregates of tau and α-synuclein, comprising the following steps: before step a) immobilisation of capture molecules on a substrate, wherein said capture molecules have specific anti-bodies against an epitope of the proteins forming the aggregates, a) applying the sample to be analysed to the substrate, wherein body fluids or tissues are used ex vivo as the sample to be analysed and wherein the sample is analysed without further processing and/or treatment for at least two different aggregate types of endogenous misfolded proteins, b) adding probes labelled for the detection which label the respective aggregate by specific binding to it, wherein antibodies are used as probes, wherein at least 2 different probes are used which differ both with respect to their specific binding to the aggregates as well as with respect to their different labeling and c) detection of the labelled aggregates, wherein the detection in step c) is carried out by means of a method with spatially resolved signal, wherein - step b) can be carried out before step a), and - the disease is selected from the group consisting of: tauopathies, Parkinson's disease and other synucleinopathies and/or Alzheimer's dementia, wherein a detection of monomers is excluded by one of the detection probes being identical to the capture molecule or both detecting an overlapping epitope, and/or by not evaluating signals with a low intensity by an intensity cut-off, and/or by cross-correlation. before step a) immobilisation of capture molecules on a substrate, wherein said capture molecules have specific anti-bodies against an epitope of the proteins forming the aggregates, a) applying the sample to be analysed to the substrate, wherein body fluids or tissues are used ex vivo as the sample to be analysed and wherein the sample is analysed without further processing and/or treatment for at least two different aggregate types of endogenous misfolded proteins, b) adding probes labelled for the detection which label the respective aggregate by specific binding to it, wherein antibodies are used as probes, wherein at least 2 different probes are used which differ both with respect to their specific binding to the aggregates as well as with respect to their different labeling and c) detection of the labelled aggregates, wherein the detection in step c) is carried out by means of a method with spatially resolved signal, a) applying the sample to be analysed to the substrate, wherein body fluids or tissues are used ex vivo as the sample to be analysed and wherein the sample is analysed without further processing and/or treatment for at least two different aggregate types of endogenous misfolded proteins, b) adding probes labelled for the detection which label the respective aggregate by specific binding to it, wherein antibodies are used as probes, wherein at least 2 different probes are used which differ both with respect to their specific binding to the aggregates as well as with respect to their different labeling and c) detection of the labelled aggregates, wherein the detection in step c) is carried out by means of a method with spatially resolved signal, wherein - step b) can be carried out before step a), and - the disease is selected from the group consisting of: tauopathies, Parkinson's disease and other synucleinopathies and/or Alzheimer's dementia, - step b) can be carried out before step a), and - the disease is selected from the group consisting of: tauopathies, Parkinson's disease and other synucleinopathies and/or Alzheimer's dementia, wherein a detection of monomers is excluded by one of the detection probes being identical to the capture molecule or both detecting an overlapping epitope, and/or by not evaluating signals with a low intensity by an intensity cut-off, and/or by cross-correlation.